UCB Acquires Celltech for £1.53 Billion: Strategic Implications and Industry Impact

June 2004

Acquisition Details : UCB, a Belgian drug company, acquired the UK's oldest biotech company, Celltech, for £1.53 billion ($2.25 billion) on May 18.

Financial Performance : In 2003, Celltech had revenues of £353 million ($641 million) and operating profits of £50 million ($91 million).

Strategic Motive : UCB was attracted to Celltech's late-stage product pipeline, particularly CDP870, projected to reach $740 million in sales by 2010.

Market Impact : The acquisition is viewed as a setback for the UK biotech sector and may negatively influence investor sentiment.

Industry Trends : The deal may signal a trend towards more cross-border mergers in European biotechnology to compete globally.

Sector Valuation : The acquisition highlights undervaluation in the UK biotech sector, with other potential candidates for acquisition identified.

Source: nature biotechnology